Sobi Q3 2026: revenue up 16% at CER and strong strategic portfolio growth
FROM THE WIRE · FINANCE.YAHOO.COM
STOCKHOLM, Oct. 27, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2026 Third Quarter 2026 Total revenue increased 16 per cent at CER (constant exchange rates), 17 per cent at actual rates, to SEK 9,124 M (7,776)…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishSolid revenue growth and haematology strength support the outlook for the biopharma group.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 revenue rose to SEK 9,124 million, up 16% at constant exchange rates.
- 02Haematology revenue grew 29% at constant exchange rates.
- 03Revenue from the strategic portfolio grew 25% at constant exchange rates.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets